Abstract
Developments in the field of adenosine receptor (AR) agonists of the past years are presented and discussed. Four different AR subtypes, A1, A2A, A2B, and A3, have been cloned from different species including the human receptors. Recombinant ARs expressed in permanent mammalian cell lines have found wide application in the screening of new ligands. Considerable differences are observed among data from different laboratories, using recombinant receptors for the assays. Reevaluation of compounds at all four receptor subtypes has shown that agonists that were believed to be selective for either A1 or A2A ARs may be potent A3 agonists and thus, nonselective. Potent and selective agonists for two of the AR subtypes, A1 and A3, have been developed. Truly selective A2A AR agonists, however, are presently not available. Potent or selective A2B agonists are still lacking. Since the treatment with AR agonists may lead to fast desensitization of the receptors, partial agonists, and indirect AR agonists, such as adenosine kinase inhibitors, or allosteric enhancers of adenosine binding, are being developed as site- and event-specific agents.
Current Medicinal Chemistry
Title: Adenosine Receptor Ligands-Recent Developments Part I. Agonists
Volume: 7 Issue: 12
Author(s): C. E. Muller
Affiliation:
Abstract: Developments in the field of adenosine receptor (AR) agonists of the past years are presented and discussed. Four different AR subtypes, A1, A2A, A2B, and A3, have been cloned from different species including the human receptors. Recombinant ARs expressed in permanent mammalian cell lines have found wide application in the screening of new ligands. Considerable differences are observed among data from different laboratories, using recombinant receptors for the assays. Reevaluation of compounds at all four receptor subtypes has shown that agonists that were believed to be selective for either A1 or A2A ARs may be potent A3 agonists and thus, nonselective. Potent and selective agonists for two of the AR subtypes, A1 and A3, have been developed. Truly selective A2A AR agonists, however, are presently not available. Potent or selective A2B agonists are still lacking. Since the treatment with AR agonists may lead to fast desensitization of the receptors, partial agonists, and indirect AR agonists, such as adenosine kinase inhibitors, or allosteric enhancers of adenosine binding, are being developed as site- and event-specific agents.
Export Options
About this article
Cite this article as:
Muller E. C., Adenosine Receptor Ligands-Recent Developments Part I. Agonists, Current Medicinal Chemistry 2000; 7 (12) . https://dx.doi.org/10.2174/0929867003374101
DOI https://dx.doi.org/10.2174/0929867003374101 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Arterial Stiffness: A Novel Cardiovascular Risk Factor in Kidney Disease Patients
Current Vascular Pharmacology Antidiabetics: Structural Diversity of Molecules with a Common Aim
Current Medicinal Chemistry Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Integrating Coronary Calcium into Risk Prediction: Current Approaches and Future Directions
Current Cardiology Reviews Enhancing Endothelial Progenitor Cell Function Through Selective Estrogen Receptor Modulation: A Potential Approach to Cardiovascular Risk Reduction
Cardiovascular & Hematological Agents in Medicinal Chemistry Estrogen Receptor-α: Plasma Membrane Localization and Functions
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Chronic Kidney Disease and the Search for New Biomarkers for Early Diagnosis
Current Medicinal Chemistry Reactive Oxygen Species in the Initiation of IL-4 Driven Autoimmunity as a Potential Therapeutic Target
Current Pharmaceutical Design Impact of Diabetes on Cardiac and Vascular Disease: Role of Calcium Signaling
Current Medicinal Chemistry Why Not All Hypertensive Patients Are Tachycardic at Rest?
Current Pharmaceutical Design Effects of Structured Treatment Interruptions on Metabolic, Anthropometric, Immunologic, and Quality of Life Outcomes in HIV-Positive Adults on HAART
Current HIV Research Dyslipidaemias and Cardiovascular Disease: Focus on the Role of PCSK9 Inhibitors
Current Medicinal Chemistry Recent Medicinal Chemistry Studies for Multitarget Agents-Part II
Current Drug Targets Mental Health Patients at High Risk for Obesity, Type 2 Diabetes, and Cardiovascular Disease: An Australian Perspective
Current Hypertension Reviews Insulin Resistance-Induced Hypertension and a Role of Perivascular CGRPergic Nerves
Current Protein & Peptide Science PDE4D Gene in the STRK1 Region on 5q12: Susceptibility Gene for Ischemic Stroke
Current Medicinal Chemistry Recent Advances in Regulatory T Cell Therapy of Autoimmunity, Graft Rejection and Cancer
Recent Patents on Inflammation & Allergy Drug Discovery Herbal Folklore Medication for Liver Disorders
Current Traditional Medicine Hyperthermia: From Diagnostic and Treatments to New Discoveries
Recent Patents on Biotechnology Cardiovascular-Active Venom Toxins: An Overview
Current Medicinal Chemistry